Vtv Therapeutics gets FDA orphan drug designation for HPPD
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
08:07:01 PM UTC
SquawkNews
Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatinHIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. NASDAQ:VTVT, a late-stage biopharmaceutical company advancing cadisegli…